Ironwood Pharmaceuticals (NASDAQ: IRWD) stock surged approximately 36% in pre-market trading after the company issued a 2026 financial guidance that far exceeded Wall Street expectations. The biotech company projects total revenue to reach $450 million to $475 million, well above the market consensus of $319.5 million, and expects adjusted EBITDA to exceed $300 million. This optimistic outlook is primarily driven by strategic price reductions for its flagship drug LINZESS, which is expected to improve net pricing and boost net sales in the US to $1.125 billion to $1.175 billion.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)